Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
By A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, K. Nakata, Y. Taguchi, S. Nagai, H. Itoh, M. Ohi and 2 more. American Journal of Respiratory and Critical Care Medicine, 2005
893 citations recorded by the source corpus.
Subfields: Physiology, Plant Science, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/f5058957444851d3e7644ce6b7774cf5b5fefee3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Interstitial lung disease guideline (2008, methodology): “A placebo (2:1) controlled double-blind phase 2 study of pirfenidone therapy in 107 Japanese patients with moderate IPF has recently been reported.(8) Planned for 1 year, the study was prematurely stopped by 9 months following an interim analysis that revealed significantly greater acute exacerbatio”
- Clinical course and prediction of survival in idiopathic pulmonary fibrosis. (2011, neutral): “trials: 1Pirfenidone (27), 2Imatinib (29), 3Interferon g-1b”
- Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. (2016, neutral): “subject subsequent trial did not replicate these results (47, 76).”
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. (2015, background): “Future nintedanib trials should focus on patients with IPF with impairment in PFTs more severe than mild to moderate.”